Gene therapy specialist bluebird exits “untenable” European marketEurope market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene Share XGene therapy specialist bluebird exits “untenable” European markethttps://pharmaphorum.com/news/gene-therapy-specialist-bluebird-exits-untenable-european-market/
From representation to empowerment: Putting patients at the centre of medicine reimbursementExperts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement Share XFrom representation to empowerment: Putting patients at the centre of medicine reimbursementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/representation-empowerment-patients-centre-medicine-reimbursement/
Patients as Partners Europe: Are we doing patient centricity all wrong?To be truly patient centric, do we need to turn the current model on its head and work Share XPatients as Partners Europe: Are we doing patient centricity all wrong?https://pharmaphorum.com/views-analysis-patients/pharma-patients-as-partners-europe-patient-centricity/
Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
The calm after the storm: How COVID-19 is making pharma more resilientCOVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning Share XThe calm after the storm: How COVID-19 is making pharma more resilienthttps://pharmaphorum.com/views-analysis-sales-marketing/the-calm-after-the-storm-how-covid19-is-making-pharma-more-resilient-and-accessible/
Germany’s digital health changes will boost digital therapeutics in EuropeDigital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating Share XGermany’s digital health changes will boost digital therapeutics in Europehttps://deep-dive.pharmaphorum.com/magazine/digital-health-innovation-2020/germanys-digital-health-changes-will-boost-digital-therapeutics/
EMA starts rapid review of Bluebird’s gene therapy for rare disease CALDBluebird bio could be just a few months away from approval of its gene therapy for rare disease Share XEMA starts rapid review of Bluebird’s gene therapy for rare disease CALDhttps://pharmaphorum.com/news/ema-starts-rapid-review-of-bluebirds-gene-therapy-for-rare-disease-cald/
Life science leaders sign new ‘Biotech Social Pact’ for EuropeThe signatories of a new Biotech Social Pact with Europe and patients explain why healthcare calls for a Share XLife science leaders sign new ‘Biotech Social Pact’ for Europehttps://pharmaphorum.com/views-analysis-market-access/life-science-leaders-sign-new-biotech-social-pact-for-europe/
Time for a health innovation pact: rethinking the design and delivery of healthcareJanssen’s Anouk De Vroey on why we need to extend the public/private partnerships resulting from COVID-19 into more Share XTime for a health innovation pact: rethinking the design and delivery of healthcarehttps://pharmaphorum.com/views-and-analysis/time-for-a-health-innovation-pact-rethinking-the-design-and-delivery-of-healthcare/
